Status:
COMPLETED
Study To Assess Long Term Safety Of Pazopanib
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study was a rollover study to evaluate the long term safety of pazopanib and to continue to provide pazopanib to patients who participated in a GSK sponsored pazopanib study until pazopanib is av...
Eligibility Criteria
Inclusion
- Key
- Participated or completed a GSK sponsored pazopanib study and remains eligible for continued treatment with pazopanib and lapatinib (if on combination therapy).
- Able to understand and provide written informed consent
- Women and men agree to use protocol specific birth control measures
- Key
Exclusion
- The subject has a treatment related serious adverse event that remains unresolved or unstable or had pazopanib permanently stopped in a previous study because of intolerate or because it was unsuccessful in treating your cancer
- If you are pregnant or breast feeding
- Your doctor does not think you would be a good candidate for the study
- Poorly controlled high blood pressure
- Subject is unwilling or unable to follow the procedures outlined in the protocol.
Key Trial Info
Start Date :
June 20 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 8 2018
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT00387205
Start Date
June 20 2006
End Date
March 8 2018
Last Update
March 6 2019
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Duarte, California, United States, 91010
2
Novartis Investigative Site
Santa Monica, California, United States, 90404
3
Novartis Investigative Site
Aurora, Colorado, United States, 80045
4
Novartis Investigative Site
Indianapolis, Indiana, United States, 46202